Discrepant studies have also shown that patients with liver cancer with a high dopamine receptor D1 (DRD1) expression had worse prognosis, and the usage of the DRD1-specific antagonist SCH23390 significantly inhibited cell invasion and migration in vitro and tumor growth in vivo (26). Here, DRD1 is linked to neoplasm.